Nonconventional Therapeutics against Staphylococcus aureus
- PMID: 30547858
- PMCID: PMC6296826
- DOI: 10.1128/microbiolspec.GPP3-0047-2018
Nonconventional Therapeutics against Staphylococcus aureus
Abstract
Staphylococcus aureus is one of the most important human pathogens that is responsible for a variety of diseases ranging from skin and soft tissue infections to endocarditis and sepsis. In recent decades, the treatment of staphylococcal infections has become increasingly difficult as the prevalence of multi-drug resistant strains continues to rise. With increasing mortality rates and medical costs associated with drug resistant strains, there is an urgent need for alternative therapeutic options. Many innovative strategies for alternative drug development are being pursued, including disruption of biofilms, inhibition of virulence factor production, bacteriophage-derived antimicrobials, anti-staphylococcal vaccines, and light-based therapies. While many compounds and methods still need further study to determine their feasibility, some are quickly approaching clinical application and may be available in the near future.
References
-
- Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Patel PR, Fridkin SK, Active Bacterial Core Surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. 2010. Health care-associated invasive MRSA infections, 2005-2008. JAMA 304:641–648 10.1001/jama.2010.1115. [PubMed] - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical